• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Targeted Next-Generation Sequencing Reveals Clinically Actionable and Mutations in Low-Grade Serous Ovarian Carcinoma.

作者信息

Stover Elizabeth H, Feltmate Colleen, Berkowitz Ross S, Lindeman Neal I, Matulonis Ursula A, Konstantinopoulos Panagiotis A

机构信息

Elizabeth H. Stover, Ursula A. Matulonis, and Panagiotis A. Konstantinopoulos, Dana-Farber Cancer Institute, Harvard Medical School; and Colleen Feltmate, Ross S. Berkowitz, and Neal I. Lindeman, Brigham and Women's Hospital, Harvard Medical School, Boston, MA.

出版信息

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00135. Epub 2018 Nov 8.

DOI:10.1200/PO.18.00135
PMID:30828692
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6394870/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7604/7594681/f864f0096a3e/PO.18.00135f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7604/7594681/9d3cca42e27b/PO.18.00135f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7604/7594681/f864f0096a3e/PO.18.00135f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7604/7594681/9d3cca42e27b/PO.18.00135f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7604/7594681/f864f0096a3e/PO.18.00135f2.jpg

相似文献

1
Targeted Next-Generation Sequencing Reveals Clinically Actionable and Mutations in Low-Grade Serous Ovarian Carcinoma.靶向二代测序揭示了低级别浆液性卵巢癌中具有临床可操作性的突变。
JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00135. Epub 2018 Nov 8.
2
Targeted Genomic Sequencing Reveals Novel In-frame Deletion Mutations Leading to p53 Overexpression in High-grade Serous Tubo-ovarian Carcinoma.靶向基因组测序揭示导致高级别浆液性输卵管卵巢癌中p53过表达的新型框内缺失突变。
Anticancer Res. 2019 Jun;39(6):2883-2889. doi: 10.21873/anticanres.13417.
3
The molecular pathology of ovarian serous borderline tumors.卵巢浆液性交界性肿瘤的分子病理学
Ann Oncol. 2016 Apr;27 Suppl 1(Suppl 1):i16-i19. doi: 10.1093/annonc/mdw089.
4
In ovarian neoplasms, BRAF, but not KRAS, mutations are restricted to low-grade serous tumours.在卵巢肿瘤中，BRAF突变（而非KRAS突变）仅限于低级别浆液性肿瘤。
J Pathol. 2004 Mar;202(3):336-40. doi: 10.1002/path.1521.
5
Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.p53 突变模式可区分卵巢浆液性交界性肿瘤以及低级别和高级别癌，并为卵巢癌发生的新模型提供支持：一项免疫组化相关性突变分析
Am J Surg Pathol. 2005 Feb;29(2):218-24. doi: 10.1097/01.pas.0000146025.91953.8d.
6
Usefulness of immunohistochemistry for the detection of the BRAF V600E mutation in ovarian serous borderline tumors.免疫组织化学在检测卵巢浆液性交界性肿瘤中BRAF V600E突变的应用价值
Oncol Rep. 2014 Nov;32(5):1815-9. doi: 10.3892/or.2014.3442. Epub 2014 Aug 25.
7
Mutation of NRAS is a rare genetic event in ovarian low-grade serous carcinoma.NRAS突变在卵巢低级别浆液性癌中是一种罕见的基因事件。
Hum Pathol. 2017 Oct;68:87-91. doi: 10.1016/j.humpath.2017.08.021. Epub 2017 Sep 2.
8
Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.采用多基因二代测序癌症检测板方法对浆液性卵巢癌进行分子特征分析。
BMC Res Notes. 2014 Nov 17;7:805. doi: 10.1186/1756-0500-7-805.
9
Expression of BRAF V600E mutant protein in epithelial ovarian tumors.BRAF V600E突变蛋白在上皮性卵巢肿瘤中的表达。
Appl Immunohistochem Mol Morphol. 2013 Mar;21(2):159-64. doi: 10.1097/PAI.0b013e31825d7402.
10
Determination of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in borderline and low-grade ovarian cancers.在交界性和低级别卵巢癌中测定BRAF V600E（VE1）蛋白表达及第600密码子处BRAF基因突变状态。
Tumour Biol. 2017 May;39(5):1010428317706230. doi: 10.1177/1010428317706230.

引用本文的文献

1
Novel Targeted Agents in Advanced and Recurrent Low-Grade Serous Ovarian Cancer: A Silver Lining in the Therapy of a Chemoresistant Disease?晚期和复发性低级别浆液性卵巢癌的新型靶向药物：难治性疾病治疗中的一线希望？
Cancers (Basel). 2024 Sep 26;16(19):3268. doi: 10.3390/cancers16193268.
2
Novel Endocrine Therapeutic Opportunities for Estrogen Receptor-Positive Ovarian Cancer-What Can We Learn from Breast Cancer?雌激素受体阳性卵巢癌的新型内分泌治疗机会——我们能从乳腺癌中学到什么？
Cancers (Basel). 2024 May 13;16(10):1862. doi: 10.3390/cancers16101862.
3
Combined aromatase, CDK4/6 and PI3K blockade using letrozole/abemaciclib/LY3023414 in endometrial cancer.

本文引用的文献

1
OncoKB: A Precision Oncology Knowledge Base.OncoKB：一个精准肿瘤知识库。
JCO Precis Oncol. 2017 Jul;2017. doi: 10.1200/PO.17.00011. Epub 2017 May 16.
2
and Mutations Co-occur and Cooperate in Low-Grade Serous Ovarian Carcinomas.并且低级别浆液性卵巢癌中存在突变共存和协同作用。
Cancer Res. 2017 Aug 15;77(16):4268-4278. doi: 10.1158/0008-5472.CAN-16-2224. Epub 2017 Jun 23.
3
Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.OncoPanel验证：一种用于检测癌症体细胞变异的靶向新一代测序分析方法
在子宫内膜癌中使用来曲唑/阿贝西利/LY3023414联合阻断芳香化酶、CDK4/6和PI3K
Gynecol Oncol Rep. 2024 Feb 22;52:101348. doi: 10.1016/j.gore.2024.101348. eCollection 2024 Apr.
4
Low-grade serous ovarian cancer: expert consensus report on the state of the science.低级别浆液性卵巢癌：科学现状的专家共识报告。
Int J Gynecol Cancer. 2023 Sep 4;33(9):1331-1344. doi: 10.1136/ijgc-2023-004610.
5
Rare Epithelial Ovarian Cancers: Low Grade Serous and Mucinous Carcinomas.罕见的上皮性卵巢癌：低级别浆液性和黏液性癌。
Cold Spring Harb Perspect Med. 2023 Sep 1;13(9):a038190. doi: 10.1101/cshperspect.a038190.
6
Detection of Mutations in Primary Tumors and Plasma Cell-Free DNA in High-Grade Serous Ovarian Carcinoma Patients.高级别浆液性卵巢癌患者原发性肿瘤和血浆游离DNA中突变的检测
Cancers (Basel). 2022 Aug 4;14(15):3790. doi: 10.3390/cancers14153790.
7
Estrogen Signaling and Its Potential as a Target for Therapy in Ovarian Cancer.雌激素信号传导及其作为卵巢癌治疗靶点的潜力。
Cancers (Basel). 2020 Jun 22;12(6):1647. doi: 10.3390/cancers12061647.
8
Low-grade Serous Tumors: Are We Making Progress?低级别浆液性肿瘤：我们是否取得进展？
Curr Oncol Rep. 2020 Jan 27;22(1):8. doi: 10.1007/s11912-020-0872-5.
Arch Pathol Lab Med. 2017 Jun;141(6):751-758. doi: 10.5858/arpa.2016-0527-OA. Epub 2017 Mar 3.
4
Clinical Implications of ESR1 Mutations in Hormone Receptor-Positive Advanced Breast Cancer.雌激素受体1（ESR1）突变在激素受体阳性晚期乳腺癌中的临床意义
Front Oncol. 2017 Mar 15;7:26. doi: 10.3389/fonc.2017.00026. eCollection 2017.
5
Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum.卵巢或腹膜低级别浆液性癌女性的激素维持治疗
J Clin Oncol. 2017 Apr 1;35(10):1103-1111. doi: 10.1200/JCO.2016.71.0632. Epub 2017 Feb 21.
6
Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer.高级别和低级别晚期浆液性上皮性卵巢癌女性的预后
Obstet Gynecol. 2017 Mar;129(3):439-447. doi: 10.1097/AOG.0000000000001867.
7
Activating Mutations Differentially Affect the Efficacy of ER Antagonists.激活突变对雌激素受体拮抗剂的疗效有不同影响。
Cancer Discov. 2017 Mar;7(3):277-287. doi: 10.1158/2159-8290.CD-15-1523. Epub 2016 Dec 16.
8
ESR1 mutations: Moving towards guiding treatment decision-making in metastatic breast cancer patients.ESR1 突变：为转移性乳腺癌患者的治疗决策提供指导。
Cancer Treat Rev. 2017 Jan;52:33-40. doi: 10.1016/j.ctrv.2016.11.001. Epub 2016 Nov 10.
9
Institutional implementation of clinical tumor profiling on an unselected cancer population.在未选择的癌症人群中进行临床肿瘤分析的机构实施。
JCI Insight. 2016 Nov 17;1(19):e87062. doi: 10.1172/jci.insight.87062.
10
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology.卵巢癌临床实践指南（2016 年版）.NCCN 肿瘤学临床实践指南
J Natl Compr Canc Netw. 2016 Sep;14(9):1134-63. doi: 10.6004/jnccn.2016.0122.